Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report; 'Eylea Static Decreasing, 2H18 Product Launches'

August 2, 2018 3:27 PM
Oppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles